Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.
The Assistance Fund will pay $4 million to resolve claims that the Florida-based charity acted as a conduit for companies including Biogen Inc. and Novartis AG to pay kickbacks to Medicare patients using their high-priced multiple sclerosis drugs, the U.S. Justice Department said.
Swiss drugmakers Novartis and Lonza separately deepened the companies’ push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.
Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.
Mallinckrodt Plc tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker that the company now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10 percent hit to annual net sales of the company’s gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as much as 34 percent.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Biogen Inc. beat analysts’ estimates for fourth-quarter profit and revenue, buoyed by higher sales of the company’s top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.